Concert Pharmaceuticals Inc (CNCE.OQ)
20 Jul 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2006||Chairman of the Board, Co-Founder|
|57||2006||President, Chief Executive Officer, Co-Founder, Director|
|2017||Principal Financial Officer, Principal Accounting Officer|
|45||2018||Chief Financial Officer|
|55||2007||Chief Operating Officer|
- BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.19
- BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata
- BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing
- BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26
- BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End